Tumor fragments from stable TG lines were implanted subcutaneously in ~4–6 week-old NOD/SCID mice. When tumor volumes reached ~300 mm3, mice were allocated into different treatment groups as previously described (Sivanand et al., 2012 ; Pavía-Jiménez et al., 2014). TAK-243 (MLN7243) (Chemietek) was administered IV every 72 hours at 25 mg/kg in 20% 2-hydroxypropyl-β-cyclodextrin (HPβCD). Rapamycin (positive control) was administered intraperitoneally at 0.5 mg/kg in 5% ethanol, 5% PEG400, 5% Tween 80, and 85% D5W every 48 hours. Mouse weight and tumor volumes were typically assessed three times per week. Tumor volume was measured using calipers and calculated as previously reported (Pavía-Jiménez et al., 2014 (link)). Data are reported as tumor means ± SD.
Tak 243 mln7243
Manufactured by Chemietek
TAK-243 (MLN7243) is a small molecule laboratory reagent. It functions as a specific and potent inhibitor of the enzyme NEDD8-activating enzyme (NAE). The core function of TAK-243 is to disrupt the NEDD8 conjugation pathway, which is involved in the regulation of various cellular processes.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using tak 243 mln7243
1
Evaluating TAK-243 and Rapamycin in Xenograft Mouse Model
2
TAK-243 and Immunoblotting Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
TAK-243 (MLN 7243) was purchased from Chemietek (CT-M7243) for in vitro and in vivo studies. The antibodies used in this study were purchased from Cell Signaling and Santa Cruz. All primary antibodies were used at 1:1000 dilutions. Corresponding HRP-conjugated secondary antibodies were used at 1:5000 dilution.
3
Evaluating TAK-243 and Rapamycin in Xenograft Mouse Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Tumor fragments from stable TG lines were implanted subcutaneously in ~4–6 week-old NOD/SCID mice. When tumor volumes reached ~300 mm3, mice were allocated into different treatment groups as previously described (Sivanand et al., 2012 ; Pavía-Jiménez et al., 2014). TAK-243 (MLN7243) (Chemietek) was administered IV every 72 hours at 25 mg/kg in 20% 2-hydroxypropyl-β-cyclodextrin (HPβCD). Rapamycin (positive control) was administered intraperitoneally at 0.5 mg/kg in 5% ethanol, 5% PEG400, 5% Tween 80, and 85% D5W every 48 hours. Mouse weight and tumor volumes were typically assessed three times per week. Tumor volume was measured using calipers and calculated as previously reported (Pavía-Jiménez et al., 2014 (link)). Data are reported as tumor means ± SD.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!